



US009914773B2

(12) **United States Patent**
Low et al.(10) **Patent No.:** **US 9,914,773 B2**
(45) **Date of Patent:** **Mar. 13, 2018**

- (54) **ANTI-HUMAN FOLATE RECEPTOR BETA ANTIBODIES AND METHODS OF USE**
- (71) Applicants: **Purdue Research Foundation**, West Lafayette, IN (US); **The United States of America, as Represented by the Secretary Department of Health and Human Services**, Washington, DC (US)
- (72) Inventors: **Philip S. Low**, West Lafayette, IN (US); **Dimitar S. Dimitrov**, Frederick, MD (US); **Yang Feng**, Frederick, MD (US); **Jiayin Shen**, San Diego, CA (US)
- (73) Assignees: **PURDUE RESEARCH FOUNDATION**, West Lafayette, IN (US); **THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 29 days.

(21) Appl. No.: **14/524,304**

(22) Filed: **Oct. 27, 2014**

(65) **Prior Publication Data**
US 2015/0110798 A1 Apr. 23, 2015

Related U.S. Application Data

(63) Continuation of application No. 13/790,881, filed on Mar. 8, 2013, now Pat. No. 8,871,206, which is a continuation-in-part of application No. PCT/US2011/050943, filed on Sep. 9, 2011.

(60) Provisional application No. 61/381,340, filed on Sep. 9, 2010.

(51) **Int. Cl.**
C07K 16/28 (2006.01)
C07K 14/705 (2006.01)
A61K 38/00 (2006.01)
A61K 9/00 (2006.01)
A61K 9/127 (2006.01)
A61K 47/48 (2006.01)
A61K 49/00 (2006.01)
A61K 49/16 (2006.01)
A61K 51/10 (2006.01)

(52) **U.S. Cl.**
CPC **C07K 16/28** (2013.01); **A61K 9/0019** (2013.01); **A61K 9/127** (2013.01); **A61K 38/00** (2013.01); **A61K 47/48561** (2013.01); **A61K 47/48823** (2013.01); **A61K 49/0058** (2013.01); **A61K 49/16** (2013.01); **A61K 51/1027** (2013.01); **C07K 14/705** (2013.01); **C07K 2317/21** (2013.01); **C07K 2317/33** (2013.01); **C07K 2317/54** (2013.01); **C07K 2317/565** (2013.01); **C07K 2317/732** (2013.01); **C07K 2317/76** (2013.01); **C07K 2317/92** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**

4,522,811 A	6/1985	Eppstein et al.
5,798,230 A	8/1998	Bornkamm et al.
6,001,329 A	12/1999	Buchsbaum et al.
2003/0232333 A1	12/2003	Ladner et al.
2008/0260812 A1	10/2008	Matsuyama et al.
2010/0055034 A1	3/2010	Martin et al.

OTHER PUBLICATIONS

Vajdos et al. (J Mol Biol. Jul. 5, 2002;320(2):415-28 at 416).*

Brown et al. (J Immunol. May 1996;156(9):3285-91).*

Antohe et al., "Increased uptake of folate conjugates by activated macrophages in experimental hyperlipemia," *Cell Tissue Res.*, 320:277-285, Feb. 16, 2005.

Antony, "The biological chemistry of folate receptors," *Blood*, 79(11):2807-2820, Jun. 1, 1992.

Ayala-Lopez et al., "Imaging of atherosclerosis in apolipoprotein e knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages," *J Nuc Med*, 51(5):768-774 Epub Apr. 15, 2010.

Bender et al., "Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture," *Hum Antibodies Hybridomas*, 4(2):74-79, Apr. 1993.

Blaser et al., "Induction of folate receptor type beta in a bone marrow engraftment model of acute myelogenous leukemia," *Leukemia*, 21:2233-2235, Epub Jun. 7, 2007.

Boerner et al., "Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes," *J. Immunol.*, 147(1): 86-95, Jul. 1, 1991.

Brown et al., "P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis," *J. Inflamm. (Lond.)*, 5:22, Dec. 4, 2008.

Chaudhary et al., "A proper amino terminus of diphtheria toxin is important for cytotoxicity," *Biochem Biophys Res Commun.*, 180(2):545-551, Oct. 31, 1991.

Chen et al., "Detection of dysplastic intestinal adenomas using a fluorescent folate imaging probe," *Mol Imaging*, 4(1):67-74, Jan.-Mar. 2005.

Chen et al., "Arthritis imaging using a near-infrared fluorescence folate-targeted probe," *Arthritis Res Ther.*, 7(2):R310-317, Epub Jan. 14, 2005.

Elnakat and Ratnam, "Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy," *Adv Drug Deliv Rev* 56(8):1067-1084, Apr. 29, 2004.

Eshhar, "The T-Body Approach: Redirecting T Cells with Antibody Specificity," *Therapeutic Antibodies (Handbook of Experimental Pharmacology)*: 181, Chernajovsky and Nissim (eds.), pp. 329-342, Dec. 13, 2007.

(Continued)

Primary Examiner — Brian Gangle

Assistant Examiner — Andrea K McCollum

(74) *Attorney, Agent, or Firm* — Wenderoth, Lind & Ponack, L.L.P.

(57) **ABSTRACT**

Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FRβ.

17 Claims, 12 Drawing Sheets